Hyperbaric Oxygen: Evidence-Based Uses, Risks and Limits

“Sixty sessions lengthen telomeres.” It is an irresistible sentence. It is also a much faster leap than the evidence allows from a laboratory finding to a promise about your body.

Hyperbaric oxygen therapy is a real medical treatment for specific problems. It is not currently a proven way to live longer. Between those positions sit interesting studies, important limits and a potentially substantial bill. This guide helps distinguish a clinical indication, an aging experiment and a wellness offer.

What happens inside a hyperbaric chamber

During hyperbaric oxygen therapy, a person breathes oxygen in an environment pressurized above normal atmospheric pressure. Higher pressure increases the amount of oxygen dissolved in plasma and changes how much can reach tissue with compromised perfusion or oxygenation.

That does not mean “more oxygen is always better”. A medical dose includes chamber type, pressure in absolute atmospheres, breathing gas, duration, air breaks, frequency and session number. It also includes the diagnosis being treated. Changing one of those pieces can change efficacy and risk.

Proposed mechanisms include effects on tissue oxygenation, swelling, defence against selected microorganisms, vascular repair and cellular signalling. They make the treatment biologically plausible and worth studying. A mechanism alone does not prove that a particular use improves an outcome that matters to a patient.

Accepted uses do not mean “works for everything”

The European hyperbaric medicine consensus classifies indications by recommendation and evidence. They include decompression sickness, gas embolism, carbon monoxide poisoning, gas gangrene and selected cases of necrotizing infection, radiation injury, ischemic wounds or compromised tissue.

This is not a shopping list for sessions. HBOT is part of treatment in some emergencies and a narrowly selected adjunct in other conditions. It does not replace surgery, antibiotics, antidotes or wound care. Authorization and reimbursement also vary between health systems.

Scenario	Right question	Warning sign
Accepted indication	Which recommendation supports this diagnosis and how does HBOT complement main treatment?	Promising an outcome without reviewing severity, timing or alternatives
Emerging use	Are there comparative trials and a clinically relevant outcome?	Presenting mechanisms or biomarkers as proven benefit
Anti-aging or wellness	Which concrete benefit was shown in people like me?	Selling a package before admitting uncertainty

What we know about hyperbaric oxygen and longevity

The most important answer fits on one line: no trial shows more years of life, less dependency or general disease prevention from HBOT in healthy people. Anti-aging research relies mainly on intermediate markers and short tests.

A 2025 systematic review of aesthetics, anti-aging and longevity found only 15 eligible papers. Its authors considered HBOT a potentially useful adjunct, but evidence was limited to support its use and cost, and they called for large trials with standardized protocols.

Limited does not mean impossible. It means we do not yet know which people, if any, gain a longevity benefit that outweighs time, cost and risk. That is the bar a clinic should clear before turning a biological signal into a programme.

The telomere study: interesting, without proven rejuvenation

The headline came from a 2020 prospective study. Thirty-five healthy adults aged 64 or older received 60 exposures. Researchers observed increases in telomere length in several immune-cell subsets and falls in some percentages of senescent T cells.

Three limitations change the interpretation:

• everyone received the intervention, without a parallel control group;
• the team measured blood immune cells, not the biological age of the whole body;
• the study did not test survival, disease, independence or long-term quality of life.

Variability was also wide in several results. A fair conclusion is that an intensive protocol was associated with cellular changes worth replicating. It is not that the chamber “reversed aging by 20%”. The guide to telomeres and aging explains why a telomere is not a lifespan clock.

VO2 max and cognition: functional signals, still narrow

A 2024 randomized trial included 63 sedentary adults older than 64. The treatment group completed 60 sessions over 12 weeks and improved relative VO2 max by an average of 1.91 mL/kg/min versus control, alongside some cardiac-perfusion measures.

This functional result is more interesting than a molecular pathway. It still does not establish longevity, effect duration or superiority to a comparable exercise programme. Nor does it turn 60 sessions into a recommended public dose. The guide to interpreting VO2 max explains why improving a marker does not automatically translate into years of life.

Another trial in healthy older adults reported cognitive and cerebral-blood-flow changes after a similar protocol. This signal needs independent replication and follow-up. It does not support selling HBOT as general dementia prevention or treatment.

Soft chambers, pressure and oxygen: a name does not ensure equivalence

“Hyperbaric” describes pressure above ambient conditions, but two devices can deliver very different exposures. A flexible lower-pressure chamber, breathing air or using a different oxygen-delivery method, does not automatically reproduce a hospital session or the cited 60-session protocols.

Before transferring a study, compare:

• achieved pressure and how it is verified;
• oxygen concentration and delivery route;
• duration, air breaks and frequency;
• authorized device, maintenance and supervision;
• population, diagnosis and study outcome.

If these pieces do not match, findings do not travel between chambers because the label sounds similar. There is also no evidence that a gentler exposure is a longevity strategy simply because it feels easier.

Risks: ear problems are common and fire matters

A systematic review and meta-analysis of 24 randomized trials, involving 1,497 participants, found more adverse effects with HBOT than in controls. Ear discomfort was the most frequent event. The authors observed more problems in courses longer than ten sessions and at pressures above 2 ATA, although pooling different studies and diagnoses does not make those points a personal safety boundary.

Possible problems include ear and sinus pain or barotrauma, claustrophobia and temporary visual changes. Neurological oxygen toxicity, seizures and lung injury are less common. Screening should consider pressure equalization, lung disease, respiratory infection, medication, glucose when hypoglycaemic treatment is used and other clinical circumstances.

Fire deserves its own paragraph. In 2025, the FDA reminded providers of serious injuries and deaths linked to HBOT-device fires. It recommended following manufacturer instructions, training staff, supervising patients, controlling materials and objects, maintaining equipment and applying specific fire-prevention measures. A centre treating this as paperwork is not offering a premium experience; it is ignoring a basic risk.

How to evaluate an offer without being a specialist

1. Start with the diagnosis. “Inflammation”, “energy” or “anti-aging” are not enough.
2. Ask for the alternative. What would happen with standard treatment, exercise or observation?
3. Get the full dose. Pressure, oxygen, time, air breaks, frequency and number of sessions.
4. Review safety. Responsible clinician, screening, device, maintenance, fire plan and response to pain or anxiety.
5. Define an outcome. It should match the problem, not a generic biomarker panel.
6. Agree when to stop. More sessions are not an answer when there is no benefit.

The guide to evaluating a longevity clinic expands on credentials, conflicts, follow-up and promises. When the clinic sells the intervention, informed consent should make the boundary between accepted and experimental use unmistakable.

Hyperbaric oxygen FAQ

What is hyperbaric oxygen therapy?

It is a treatment in which a person breathes oxygen inside a chamber pressurized above normal atmospheric pressure. Pressure, oxygen concentration, duration and air breaks are part of the dose; not every chamber or session reproduces a studied medical intervention.

Which conditions have medical evidence?

Consensus recommendations include decompression sickness, gas embolism, carbon monoxide poisoning and selected radiation injuries, infections, wounds or compromised tissues. Recommendation, priority and coverage vary by diagnosis and country, and HBOT is often an adjunct to the main treatment.

Does a hyperbaric chamber reverse aging or extend life?

It has not been shown to reverse whole-body aging or extend life. Small studies have examined cellular markers, cognition, perfusion and physical capacity, but none demonstrates longer survival, less dependency or general prevention in healthy people.

Does hyperbaric oxygen lengthen telomeres?

An uncontrolled study in 35 older adults found changes in immune-cell telomere length after 60 sessions. This is an exploratory signal, not a measure of whole-body rejuvenation. We do not know whether it replicates or produces a durable clinical benefit.

How many sessions are needed?

That depends entirely on the indication and protocol. The 60 sessions used in some aging studies are not a validated longevity dose. A centre should explain the target, pressure, oxygen, frequency, response criteria and reason to continue or stop.

Is a soft chamber equivalent to a medical chamber?

Do not assume so. Pressure, breathing gas, device, supervision and authorized indication may differ. If a chamber does not reproduce a study protocol, its findings cannot be transferred because the name sounds similar.

What are the risks of hyperbaric oxygen?

Ear pain or barotrauma is the most frequent adverse effect. Sinus pressure, claustrophobia and temporary visual changes can occur; oxygen toxicity, seizures or lung injury are less common. Concentrated oxygen also increases fire risk.

What should I ask before paying for treatment?

Ask which diagnosis is being treated, what evidence supports that use, what alternative exists, who supervises, which device and protocol are used, how fire and barotrauma are prevented, what outcome will be measured and what happens if it does not improve. For anti-aging, ask for a clear statement that benefit is unproven.

Sources

1. Mathieu D et al. European consensus on accepted and non-accepted HBOT indications. Diving and Hyperbaric Medicine. 2017.
2. Fisher SM et al. HBOT in aesthetics and anti-aging: systematic review. Aesthetic Plastic Surgery. 2025.
3. Hachmo Y et al. Telomeres and immunosenescence after HBOT. Aging. 2020.
4. Hadanny A et al. Physical performance in older adults after HBOT. BMC Geriatrics. 2024.
5. Hadanny A et al. Cognition and cerebral blood flow in older adults after HBOT. Aging. 2020.
6. Zhang Y et al. Adverse effects of HBOT: systematic review and meta-analysis. Frontiers in Medicine. 2023.
7. U.S. Food and Drug Administration. Safe use of HBOT devices. 2025.

Method: narrative review of the linked consensus, trials, systematic review and safety communication. Biomarkers are not presented as rejuvenation, and accepted uses are not treated as individual recommendations. Sources checked 29 August 2026. This article is educational and does not replace a medical indication.